# Pedro Herranz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pedro-herranz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,251 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 34 |
| i10-index | 94 |
| Last Known Institution | Hospital Universitario La Paz |
| OpenAlex ID | https://openalex.org/A5071771485 |
| ORCID iD | 0000-0002-9840-6628 |
| Works | 231 |

## Researcher papers

- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches](https://scholariq.org/papers/cyclosporine-use-in-epidermal-necrolysis-is-associated-with-an-important/)
- [Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting](https://scholariq.org/papers/safety-and-effectiveness-of-ustekinumab-and-antitumour-necrosis-factor-therapy/)
- [Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings](https://scholariq.org/papers/prevalence-of-mucocutaneous-manifestations-in-666-patients-with-covid-19-in-a/)
- [Cutaneous small vessel vasculitis secondary to COVID‐19 infection: a case report](https://scholariq.org/papers/cutaneous-small-vessel-vasculitis-secondary-to-covid-19-infection-a-case-report/)
- [Postmenopausal frontal fibrosing alopecia](https://scholariq.org/papers/postmenopausal-frontal-fibrosing-alopecia/)
- [Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment](https://scholariq.org/papers/sensitivity-and-specificity-of-the-lymphocyte-transformation-test-in-drug/)
- [Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population](https://scholariq.org/papers/significant-hla-class-i-type-associations-with-aromatic-antiepileptic-drug-aed/)
- [Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial](https://scholariq.org/papers/long-term-2-year-safety-and-efficacy-of-tralokinumab-in-adults-with-moderate-to/)
- [Patient Burden And Impact Of Moderate-to-Severe Atopic Dermatitis In the Spanish Healthcare System: The APOLO Cross-Sectional Study](https://scholariq.org/papers/patient-burden-and-impact-of-moderate-to-severe-atopic-dermatitis-in-the-spanish/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Drug-Induced Adverse Reactions](https://scholariq.org/topics/drug-induced-adverse-reactions/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [Hospital Universitario La Paz](https://scholariq.org/institutions/hospital-universitario-la-paz/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.